APGE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.980

-18.33%

-1.220

+28.42%

-1.340

+18.58%

Estimates Revision

The market is revising No Change the revenue expectations for Apogee Therapeutics, Inc. (APGE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 59.86%.

EPS Estimates for FY2025

Revise Downward

-8.99%

In Past 3 Month

Stock Price

Go Up

+59.86%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 95.00 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

70.00

Averages

95.00

High

115.00

Current: 0.000

Low

70.00

Averages

95.00

High

115.00

Craig-Hallum

Buy

maintain

$109 -> $116

2026-01-07

New

Reason

Craig-Hallum

Price Target

$109 -> $116

2026-01-07

New

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Apogee Therapeutics to $116 from $109 and keeps a Buy rating on the shares. Apogee comes out swinging in 2026 with encouraging Phase 1b asthma data for zumilokibart that, in the firm's view, validate depth/durability and supports a pipeline-in-a-product narrative with a plausible path to every 3-6-month dosing across multiple inflammation and immunology indications. Management plans to announce additional asthma program details later this year and additional Phase 1b data at a medical meeting, Craig-Hallum adds. The firm would lean into POC in asthma and durability as the key takeaway from this data ahead of three atopic dermatitis datasets in 2026 that should further define dose response, durability, and differentiation.

Wolfe Research

Peer Perform

initiated

2026-01-07

New

Reason

Wolfe Research

Price Target

2026-01-07

New

initiated

Peer Perform

Reason

Wolfe Research initiated coverage of Apogee Therapeutics with a Peer Perform rating and no price target. While asthma appeared to have been a minor catalyst, any future success could have long-term implications, the analyst tells investors. However, with that said, "convenience euphoria has blasted the stock to all-time highs," adds the analyst, who foresees two negative catalysts in the first half of the year, followed by a high-conviction positive catalyst in the second half.

Stifel

Buy

maintain

$95 -> $133

2026-01-06

New

Reason

Stifel

Price Target

$95 -> $133

2026-01-06

New

maintain

Buy

Reason

Stifel raised the firm's price target on Apogee Therapeutics to $133 from $95 and keeps a Buy rating on the shares following positive Phase 1b asthma data for zumilokibart. Apogee's Phase 1b data "represents clear evidence of activity" that should support accrual of meaningful credit in the stock and further support for the pipeline-in-a product thesis, the analyst tells investors.

BTIG

Buy

maintain

$128 -> $137

2026-01-06

New

Reason

BTIG

Price Target

$128 -> $137

2026-01-06

New

maintain

Buy

Reason

BTIG raised the firm's price target on Apogee Therapeutics to $137 from $128 and keeps a Buy rating on the shares. A key goal for zumilokibart is to emerge as the first IL-13 inhibitor with dual asthma and atopic dermatitis labeling, and the firm sees high odds of that materializing following today's results. BTIG is increasing its probability of success of zumilokibart in asthma to 85% from 60%. Phase 1b results reported today in mild-to-moderate asthma land well into BTIG's blue sky scenario, it adds.

BofA

Tim Anderson

Buy

maintain

$81 -> $84

2026-01-06

New

Reason

BofA

Tim Anderson

Price Target

$81 -> $84

2026-01-06

New

maintain

Buy

Reason

BofA analyst Tim Anderson raised the firm's price target on Apogee Therapeutics to $84 from $81 and keeps a Buy rating on the shares. The company shared "promising" interim data from its Phase 1B study in asthma with zumilokibart and confirmed plans to progress into late-stage development, the analyst tells investors in a research note. The firm currently models $2B in nominal peak sales for Apogee in asthma, with estimated U.S./ex-U.S. launches in 2030/2031.

BTIG

Buy

maintain

$115

2025-12-29

Reason

BTIG

Price Target

$115

2025-12-29

maintain

Buy

Reason

After Johnson & Johnson (JNJ) recently reported that the Phase 2b DUPLEX-AD proof-of-concept study of JNJ-95475939 for the treatment of moderate to severe atopic dermatitis did not meet the bar set for efficacy, BTIG said the firm views this update as "a positive clearing event" for Apogee Therapeutics' (APGE) APG279 and potentially APG777 as well. The firm reiterates a Buy rating and $115 price target on Apogee shares.

Valuation Metrics

The current forward P/E ratio for Apogee Therapeutics Inc (APGE.O) is -17.23, compared to its 5-year average forward P/E of -12.33. For a more detailed relative valuation and DCF analysis to assess Apogee Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.33

Current PE

-17.23

Overvalued PE

-7.93

Undervalued PE

-16.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.73

Current EV/EBITDA

-13.68

Overvalued EV/EBITDA

-2.10

Undervalued EV/EBITDA

-11.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 2216.65% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

APGE News & Events

Events Timeline

No data

News

9.0

01-06NASDAQ.COM

PinnedApogee Therapeutics Reports Interim Phase 1b Results for APG777 in Asthma Today

5.0

00:06 AMFool

Apogee Therapeutics CMO Sells 10,900 Shares for $817,500

8.0

01-07NASDAQ.COM

APGE Options Offer 9.33% Yield Boost on $75 Put Contract

People Also Watch

Frequently Asked Questions

What is Apogee Therapeutics Inc (APGE) stock price today?

The current price of APGE is 75.52 USD — it has decreased -4.34 % in the last trading day.

What is Apogee Therapeutics Inc (APGE)'s business?

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

What is the price predicton of APGE Stock?

What is Apogee Therapeutics Inc (APGE)'s revenue for the last quarter?

Apogee Therapeutics Inc revenue for the last quarter amounts to -71.28M USD, increased 21.46 % YoY.

What is Apogee Therapeutics Inc (APGE)'s earnings per share (EPS) for the last quarter?

Apogee Therapeutics Inc. EPS for the last quarter amounts to -54255000.00 USD, increased 25.37 % YoY.

What changes have occurred in the market's expectations for Apogee Therapeutics Inc (APGE)'s fundamentals?

How many employees does Apogee Therapeutics Inc (APGE). have?

Apogee Therapeutics Inc (APGE) has 196 emplpoyees as of January 08 2026.

What is Apogee Therapeutics Inc (APGE) market cap?

Today APGE has the market capitalization of 5.39B USD.